Michael Riebe
Directors
Board of Directors
sastuma pharmaceuticals
Japan
Biography
Dr. Riebe is the Vice President of Inhalation Product Development at AstraZeneca. He has more than 25 years of experience developing pharmaceutical products, with a particular focus on inhaled- and intranasal-route products. During his career, he played a significant role in developing and launching six major new products, including Serevent™, Ventolin HFA™, Advair HFA™ and Bevespi Aerosphere. Most recently, Dr. Riebe was Senior Vice President of Pharmaceutical Development and Research at Pearl Therapeutics (acquired by AstraZeneca in 2013). Since June 2016, he has been responsible for AstraZeneca’s Inhalation Product Development group, which provides end-to-end development of inhaled products at the corporation and includes legacy AstraZeneca, Sofotec and Pearl organizations. He previously served as Vice President of R&D at iCeutica and held scientific and strategic roles at Merck & Co., Inc. and GSK. Dr. Riebe received his Ph.D. in Analytical Chemistry from the University of Wisconsin-Madison, and his B.A. in Chemistry from Kalamazoo College.
Research Interest
Pharmaceutical Science
